Effect of Iron-fortified Pea Powder on Exercise Performance

NCT ID: NCT04872140

Last Updated: 2022-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-03

Study Completion Date

2022-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study assesses the impact of an pea protein supplement with high iron bio-availability on iron status and exercise performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Female endurance athletes are susceptible to iron deficiency due to poor iron intake from diets or possibly because of destruction of red blood cells during foot-strike hemolysis. This study will evaluate the impact of 8-weeks of iron supplementation through consumption of a pea-protein power that has high iron bio-availability due to low phytate levels. This will be compared to consumption of regular iron protein powder and maltodextrin placebo by randomizing participants to three groups. Participants will be assessed at baseline and after 8 weeks of supplementation for exercise performance (maximal aerobic capacity and a 5 km time trial running test), blood levels of ferritin and hemoglobin, and body composition (fat mass and lean tissue mass).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron-deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants are being randomized to three groups for the 8-week intervention:

1. Pea power with high iron bio-availability
2. Regular pea powder
3. Placebo (maltodextrin)
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
The powder supplements are being administered in a blinded manner. An individual who is separate from the rest of the research team will generate the allocation schedule and prepare the supplement packages so that participants, investigators, and outcome assessors are blinded. Statistical analysis will be blinded by coding of groups

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pea power with high iron bio-availability

Pea powder with low phytate levels to increase iron bio-availability (7mg iron per day)

Group Type EXPERIMENTAL

Low phytate pea powder

Intervention Type DIETARY_SUPPLEMENT

Exercise performance with low phytate pea powder

Pea powder

Pea powder with normal phytate levels (7mg iron per day)

Group Type ACTIVE_COMPARATOR

Regular pea powder

Intervention Type DIETARY_SUPPLEMENT

Exercise performance with regular pea powder

Placebo

Placebo (maltodextrin) powder (0g iron per day)

Group Type PLACEBO_COMPARATOR

Placebo (maltodextrin)

Intervention Type DIETARY_SUPPLEMENT

Exercise performance with placebo (maltodextrin)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low phytate pea powder

Exercise performance with low phytate pea powder

Intervention Type DIETARY_SUPPLEMENT

Regular pea powder

Exercise performance with regular pea powder

Intervention Type DIETARY_SUPPLEMENT

Placebo (maltodextrin)

Exercise performance with placebo (maltodextrin)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female
* Regularly participate in aerobic endurance training

Exclusion Criteria

* Any contra-indications to exercise testing as determined with the "Get Active Questionnaire"
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Saskatchewan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Phil Chilibeck

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philip Chilibeck, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Saskatchewan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Shaw KA, Chilibeck PD, Lindsay DL, Warkentin TD, Ko J, Zello GA. Low phytic acid pea supplementation as an approach to combating iron deficiency in female runners: A randomized control trial. Nutr Health. 2025 Mar;31(1):293-301. doi: 10.1177/02601060231181605. Epub 2023 Jun 8.

Reference Type DERIVED
PMID: 37291968 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1207

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Iron and Muscle Study
NCT04862715 COMPLETED PHASE4